Avapritinib follow-up study for previous trial participants
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This study provides continued access to avapritinib for people who have already been in a Blueprint Medicines trial and are still benefiting from the drug. It allows you to keep receiving treatment while staying monitored for safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were in a previous Blueprint Medicines avapritinib study and completed the final visit for that study.
- You are still getting clinical benefit from avapritinib (your doctor agrees the drug is helping you).
- You are not currently in any other interventional clinical trial (a trial that tests a treatment).
- You are willing to follow study rules, such as using highly effective birth control if needed and having pregnancy tests if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study provides continued access to the drug mitapivat for people who have already been in a mitapativ study and are benefiting from it.
This study looks at how avapritinib works in people with indolent systemic mastocytosis whose symptoms are not well controlled by other treatments. You will take the drug as part of your usual care, and researchers will collect information to see how well it helps.
This trial tests a combination of two drugs, avapritinib and decitabine, for people with systemic mastocytosis plus another blood cancer (SM-AHN). The goal is to see if the combination works better than either drug alone.
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
This study is observing adults with indolent systemic mastocytosis (ISM) who are already receiving or planning to start symptom treatments or the drug avapritinib. It aims to learn more about how these treatments work in real life.
Hear when a new Mastocytosis, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.